Date: 2017-08-10
Type of
information: Initiation of patient enrollment
phase: 1
Announcement: initiation of patient enrollment
Company: CARsgen Therapeutics (China)
Product: anti-Claudin18.2-CAR-T cell therapy
Action
mechanism:
- cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy. Claudin18.2 belongs to a family of membrane proteins that make tight junctions. Previous research has shown that its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa, but is abundant in a variety of human malignancies including gastric, pancreatic, and esophageal cancer, which qualify CLDN18.2 as a highly attractive target to develop safe and potent cancer immunotherapies.
Disease: gastric cancer, pancreatic cancer
Therapeutic
area: Cancer - Oncology
Country: China
Trial
details: This single arm, open-label pilot study is designed to determine the safety, tolerability and engraftment of CAR-CLD18 T cells in patients with advanced gastric adenocarcinoma and pancreatic adenocarcinoma. (NCT03159819)
Latest
news:
- • On August 10, 2017, CARsgen Therapeutics, a chinese company developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, announced its first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers has entered into phase I clinical trial and starts patients recruitment at Changhai Hospital of Shanghai.
Is
general: Yes
